

# DREAMADERM



— FIRST-IN-CLASS COSMECEUTICALS —

**OPEN YOUR SKIN TO  
DREAMADERM**

**50 years of discovery delivers the new  
path for skins natural collagen  
stimulation and regeneration**

## Focus

# Wound Healing Aesthetics and Skincare

Advanced **Wound healing, cosmetic treatments** and **skincare** depend upon **collagen production**



As aging reduces collagen, leading to skin issues, there's an increasing demand for science-driven methods to boost its production. New, evidence-based, collagen-enhancing techniques are now essential in the skincare industry.



anti-aging skin care



wound healing

**There is a significant market for products that accelerate collagen production**

# Naturally Enhanced Collagen Stimulation & Production

**Bringing real science to cosmetics, wound care and medical aesthetics.**

**DREAMADERM** is predicated on a novel approach to naturally enhance **collagen stimulation and production**, with major implications for the **cosmetics** and **wound healing** sectors.



## The core technology is

A **first-in-class cosmeceutical** that promotes collagen production through a novel mechanism of action, patented by UCI and developed by Dr. Malcolm A. Leissring at the University of California, Irvine.

Introducing: **Dermatrix™**

**DREAMADERM has charted a clear path to market a targeted suite of products exploiting this core technology:**



Acute  
wound care products



High-end  
aesthetic and  
cosmetic formulations



Advances Medical  
product lines for non-  
and  
slow-healing chronic  
wounds

# Problem & Solution

## DREAMADERM's core technology promotes and accelerates collagen production through an entirely new, science-based approach.



**Collagen** production is absolutely essential for wound repair, and is also a principal goal of cosmetic treatments. Our technology exploits collagen production regulated by insulin.



**Insulin** is the key molecule responsible for fuelling cells to produce collagen. However, insulin in the skin is being continuously destroyed by **insulin-degrading enzyme (IDE)**, which is abundant in wound fluid.

**Our patented, first-in-class protease inhibitor, Dermatrix**, blocks insulin degradation, thereby maximizing insulin levels.

Insulin levels without **Dermatrix**

IDE




Insulin (●) removed by IDE  
↓ collagen production  
wound healing

Insulin levels with **Dermatrix**



Insulin (●) preserved by inhibiting IDE  
↑↑ collagen production  
wound healing

# Dermatrix Applications



**Dermatrix**

Leissring *et al.*, *PLoS ONE*, 2010  
**Maianti *et al.*, *Nature*, 2014**  
 Suire *et al.*, *PLoS ONE* 2018

Abdul-Hay *et al.*, *J Med Chem* 2013  
 Abdul-Hay *et al.*, *ACS Chem Biol*, 2015  
 Adamek *et al.*, *ChemMedChem*, 2021

IDE inhibitors have been shown to **increase insulin levels and insulin action in vivo**. For instance, a paper published by Dr. Leissring and other Harvard colleagues in the top journal, *Nature*, showed that this class of compounds exhibit multiple antidiabetic properties and—critically—increase the levels of insulin by blocking this enzyme.

**Dermatrix** is a highly potent molecule composed of **all-natural amino acids**, making it relatively inexpensive to manufacture in a cGMP-compliant laboratory, costing less than \$0.50 per treatment at scale.

**Dermatrix** and related peptides can be used alone but, notably, could be combined with many products to serve several verticals, including skincare, acute wound healing, med-spa procedures/recovery, cosmetics, post surgery topicals and as an approved treatment for chronic wounds, particularly those related to type-2 diabetes.

# Scientific Evidence


**Dermatrix** represents the culmination of more than 22 years of effort by Dr. Leissring and other colleagues conducted at multiple prestigious institutions:




**Dermatrix** potentiates several insulin-induced processes in skin models

- increases transcription of **collagen mRNA**
- augments production of **mature collagen protein**
- enhances **secretion of collagen** into the extracellular matrix
- stimulates the **migration of keratinocytes**


### Collagen mRNA



### Collagen-specific amino acid (hydroxyproline)



### Collagen protein



Dermatrix

# Unique Selling Proposition

IDE inhibitors represent a **new branch of pharmacology**.

Dr. Leissring pioneered this field and is widely recognized as the leading expert in the biology and pharmacology of IDE.


He is currently developing novel IP for expanded applications.

**Dermatrix** was developed to maintain the local skin's insulin at its highest possible level and within wounds during the healing process, while at the same time being cost effective and entirely nontoxic.

**Dermatrix** was designed explicitly for topical applications.



**Dermatrix** and related peptides are covered under U.S. Patent No. 11,555,055, issued January 17, 2023.



DREAMADERM



UCI Beall  
Applied Innovation



The development of **Dermatrix** has been supported by funding from:

- **American Diabetes Association** \$ 1 million
- **National Institutes of Health** \$ 4 million
- **UCI Beall Applied Innovation** \$ 100,000

Future federal grants available for the next stages include:

- **SBIR and STTR grants** \$ 2.4 million each
- **Dept. of Health and Human Services**

**UCI** will be an equity partner with **DREAMADERM**, granting us access to:

- **UCI BAI business incubator**
- **Innovation Corps training programs**
- **Office and wet lab space via University Lab Partners**


Global Market

# Market Size

The global peptide therapeutics market size was estimated at \$43.11 billion in 2022 and is expected to reach \$76.83 billion by 2032. This will increase drastically as GLP-1 drugs are advancing beyond expectations.

# 5.94%

CAGR from 2023 to 2032



The global peptide therapeutics market



Wound Healing

# \$23B

Projected market by 2027



Skincare Worldwide

# \$150B

Projected market by 2027



Business Model

# Launch Distribution


Mexico Mfg & Mexico Distribution

<b>130M</b>	<b>51M</b>
Population	Annual Tourism

**Path to Consumer Mexico**

- **Wholesalers**
  - Pharmacies >80,000
  - Grocery
  - Big Box
  - Convenience Stores
  - Gas Stations
  - Tattoo Shops
  - Veterinarians
  - Private Healthcare Providers
- **Healthcare Institutions**
  - Hospitals (Public/Private)
- **Online Sales**
- **Relationship Marketing**
  - MX National Healthcare Union Membership 1.2 Million

## INITIAL TARGET MARKETS



Mexico Mfg & LATAM Distribution

<b>667M</b>	<b>78M</b>
Population	Annual Tourism

Global Market

# Diabetes Market Size

**537 Million** adults are living with diabetes.



More than **1 in 10** people have diabetes in the United States.

537M  
2022

643M  
2030

1.31B  
2050

Diabetes caused at least




In health expenditure a **316%** increase over the last 15 years.

Overall, global diabetes-related health expenditure is estimated to rise to



by 2045



- North America and Caribbean (51M)
- Europe (61M)
- Africa (24M)
- Western Pacific (206M)
- South and Central America (32M)
- Middle East and North Africa (73M)
- South East Asia (90M)

\*Source: IDF atlas 10th edition

Global Market

# Go To Market Strategy

Building on our patented, game-changing technology and its ability to accelerate the body's own natural processes, **DREAMADERM** has secured significant wholesale, retail and healthcare distribution in multiple markets. As a "Made in USA" ingredient, products containing **Dermatrix** will support higher profit margins. The Mexico initial conservative points-of-sale commitments will drive immediate revenues while allowing significant and achievable regional scaling capabilities.



**Phase 1a**

- Acute
- Liquid Bandage
- Chronic

Retail General Wound Healing

**Phase 1b**

- Burn Blister
- Friction Blister
- Viral Blister

Retail Targeted Wound Healing

**Phase 1c**

- Daily Line
- Derm Masks
- Device

Retail Skincare

**Phase 1d**

- Needling
- Serums
- Derm Masks
- Devices

Retail Aesthetics

**Phase 2a**

- Needling
- Serums
- Derm Masks
- Devices

Spa Aesthetics

**Phase 2b**

- Needling
- Serums
- Masks / Sheets
- Devices
- Fillers
- PDO Threads
- Botulinum TA

Medical Aesthetics / Derm

**Phase 2c**

- Needling
- Serums
- Masks / Sheets
- Device

Medical / Derm

Initial (Based on Regulatory)	Phase in (Based on Regulatory)
<ul style="list-style-type: none"> <li>• Mexico</li> <li>• Korea/Asia</li> <li>• Latin America</li> </ul>	<ul style="list-style-type: none"> <li>• Middle East</li> <li>• Europe</li> <li>• USA</li> </ul>

## Bringing together Regeneration and Acceleration

DREAMADERM is taking wound-care, skincare and advance aesthetics / medical to a new level by combining first-in-class **Dermatrix** with some of the best **Exosome** technology in the world into uniquely formulated products that stand on their own. We call this **DERM-EXO** Infusion. Your skin will feel the difference and you will not have to squint your eyes to see the results! OPEN YOUR SKIN TO DREAMADERM

### NEO-AID

ACCELERATED RECOVERY

**Retail & Healthcare Wound Healing**

Gels-Sprays-Coating-Irrigators

**Dermatrix & Exosome Infused**

- Cuts
- Scrapes
- Scratches
- Stitches
- Burns
- Blisters
- Ulcers
- Abscess
- Cuticle Care
- Viral Outbreak
- Chapped Lips
- Sunburns

The applications are endless

### DREAMADERM

ACCELERATED SKINCARE

**Retail & Spa Skincare**

Clear & Clean Daily Line

**Dermatrix & Exosome Infused**

- Cleanser
- Toner
- Day Clear HydroGel
- Night Clear HydroGel
- Spot Lift HydroGel
- Galvanic HydroGel Serum
- Radiance Lift Mask
- Galvanic Treatment Device

### NEO-DERM

ACCELERATED AESTHETICS

**Retail, Spa & Aesthetics / Medical**

Advanced Targeted Delivery Line

**Dermatrix & Exosome Infused**

- Procedure Glide Gels
- Micro/Meso-Needling Serums
- Ablative Procedure Recovery
- Indication Based Masks / Sheets
- Advance Wound Recovery
- PRP & PDO Threading Enhancer
- Fillers
- Botulinum Toxin A
- PDO Threads
- Galvanic Absorption Therapy Devices
- Micro / Meso Needle Therapy Devices
- Total Dermatological Therapy Devices

# Wound Healing Products

## Retail & Direct to Consumer

### NEO-AID

ACCELERATED DERM RECOVERY

### Acute

- Cuts
- Scrapes
- Burns
- Stitches



Topical Gel or Spray  
**Derma**matrix *Infused HydroGel*

## Healthcare Provider Distribution

### NEO-AID

ACCELERATED DERM RECOVERY

### Chronic

- Ulcers
- Abscess
- Burns
- Grafts



Topical Gel or Spray  
**Derma**matrix *Infused HydroGel*

## Retail & Direct to Consumer

### NEO-AID

ACCELERATED DERM RECOVERY

### Liquid Bandage

- Cuts
- Blisters
- Stitches



Topical Brush on Gel  
**Derma**matrix *Infused HydroGel*

(Country & Market distribution are based on local regulatory approvals)

# Blister Healing Products

Retail & Direct to Consumer

**NEO-AID**  
ACCELERATED DERM RECOVERY



**Blister**

Friction  
Thermal Burn



Lance > Irrigate

**Irrigating Gel**  
*Dermatrix Infused HydroGel*

Retail & Direct to Consumer

**NEO-AID**  
ACCELERATED DERM RECOVERY

**Blister**

Thermal Burn  
Sun Burns



**Topical Gel or Spray**  
*Dermatrix Infused HydroGel*

Retail & Direct to Consumer

**NEO-AID**  
ACCELERATED DERM RECOVERY

**Viral**

Cold Sores  
Fever Blisters



**Topical Gel**  
*Dermatrix Infused HydroGel*

(Country & Market distribution are based on local regulatory approvals)

Retail Skincare  
**Products**

# DREAMADERM

Accelerated Skincare

Retail Skincare  
Daily Series  
**DERM-EXO** Infused



Skincare Launch Line

Topical Indication G-Serums



Get-It-Deep  
G-Serum  
Galvanic Enhancer



Lock-It-In  
Cold Hammer

(Country & Market distribution are subject to local regulatory approvals)

Retail Aesthetics  
Products

# DREAMADERM

Accelerated Aesthetics

Retail Aesthetics  
At Home Treatment Series  
**DERM-EXO** Infused



Daily Serum



Meso-Therapy Indication Hydro Serums



Lidocaine Prep



Meso Roller & Stamp



Meso Pen

(Country & Market distribution are subject to local regulatory approvals)



# Aesthetics Products

# NEO-DERM ACCELERATED AESTHETICS

## Aesthetics Services to Consumer Spa Treatment Series DERM-EXO *Infuse*



Glide Gel



Ablative Recovery



Needling Prep



Meso-Therapy Indication Hydro Serums



Professional Meso Therapy Device



Micro Needle

(Country & Market distribution are subject to local regulatory approvals)

Aesthetics / Derm Medical  
**Products**

**NEO-DERM**  
ACCELERATED AESTHETICS

**Advanced Aesthetics / Derm Medical  
Treatment Series**

The image displays a variety of Neo-Derm aesthetic products. On the left, three boxes of Cross-Linked HA Fillers With Lidocaine are shown: 'SOFT' (blue 'S'), 'MOLD' (green 'M'), and 'VOLUME' (red 'V'). In the center, there are two sets of vials for PRP Enhancer DERM-EXO Enhanced (one 1ml Lyophilized and one 2ml Diluent) and PLLA Plus DERM-EXO Enhanced (one 1ml Lyophilized and one 2ml Diluent). Below these are vials for Botulinum Toxin A (DREAMTOX) and PDO Thread Enhancer DERM-EXO Enhanced (one 1ml Lyophilized and one 2ml Diluent). To the right, a diagram illustrates PDO Threading with three different thread types (grey, blue, and orange) and a woman's face with white arrows indicating treatment areas on the forehead, cheeks, and jawline.

(Country & Market distribution are subject to local regulatory approvals)

Medical / Derm  
**Products**

**NEO-DERM**  
ACCELERATED AESTHETICS

**Professional Services to Consumer**  
Medical Treatment Series  
**DERM-EXO+ Infused**



Therapeutic Masks & Sheets



Chronic Skincare Series



Advanced Stage Serums



Full Therapeutics Medical Device

(Country & Market distribution are subject to local regulatory approvals)

Partners


# Strategic Partners



**UCI Beall Applied Innovation**  
 Grant Acquisition •  
 Lab Incubator •



**Vitalia**  
 • Salud Esmeralda USA  
 • MX Master Distributor/ Packaging



**Colonial Dames USA**  
 Cosmetics Formulation •  
 Bulk Manufacturing /USA Distribution •




**University of California, Irvine**  
 • Patent Holdings  
 • Equity Partner



**National Healthcare Union of Mexico**  
 Clinical Trials Facilitator •  
 Relationship Mkt/Distribution •



**REJIMUS**  
 • Regulatory • Guidance  
 • Compliance • Strategies




Our initial partnerships have been established through long standing relationships that have endured the tests of time. As we stretch out globally, we will continue to build these partnerships around global:

- **Science/Research/IP**
- **Regulatory/Compliance**
- **Distribution/Marketing**
- **Retail/Medical**

# Consolidated Preview

(All Products, Regions and Operations)

Five Years




# POS Preview

(All Regions)

	<u>Year 1</u>	<u>Year 2</u>	<u>Year 3</u>	<u>Year 4</u>	<u>Year 5</u>
Avg Points of Sale	2,582	8,084	14,670	14,670	14,670
Avg SKU/Day/Pt	2.37	2.20	1.87	1.87	1.87

# Margin Preview

(All Regions)



# Future Product Lines and IP Development



Through on-going R&D activities, Dr. Leissring has discovered additional compounds, **including derivatives of Dermatrix** and **other small molecules**, specifically formulated for inclusion in an expanded range of cosmetic products, including our serums, skin creams, makeup, anti-wrinkle formulations and other high-volume consumer items.

**DREAMADERM** intends to complete these R&D efforts and file for additional patents and regulatory filings to protect these compounds and the unique products containing them.

There is also abundant opportunity to **license Dermatrix** these novel compounds to other companies in the cosmetics industry such as; L'Oreal, Estee Lauder, J&J, Abbvie, Unilever and others. While our initial **focus will remain on retail and high-end med-spa** applications of **our technology**, this expanded product line and potential licensing agreements will provide additional profit potential for **DREAMADERM** while also bringing increased recognition to our brand as an **emerging, science-based cosmetics company**.

# Funding



The company expects to access the **capital markets** in order to fund its projected business model as referenced in its **five (5) year** pro forma data included in this PowerPoint presentation through various financial instruments and equity.

Financial	Partnerships
<b>Initial capital raise:</b>	<b>IP licensing</b>
<b>\$2-5M</b>	<b>C-suite</b>
	<b>KOLs</b>

## \$2 – 5M

DREAMADERM’s assets were purchased on 1-23-2024 by OTC Markets listed Pacific Software (PFSF) doing business as DREAMADERM until the name is changed. The company is actively pursuing \$2 – 5M in debt and/or equity funding.

## Core Startup Executive Team

DREAMADERM



---

**Harrysen Mittler**  
*CEO / Chairman*



---

**Dr. Malcolm A. Leissring**  
*President / CSO*



---

**Stephen Israel**  
*COO*



---

**Jim DiPrima**  
*CFO*



---

**Dr. Jacqueline Jacques**  
*Strategic Advisor*

## Initial Post-Funding Executive Positions



## Initial Post-Funding Advisors/Consultants/Legal



DREAMADERM






# DREAMADERM

— ADVANCED SKIN CARE —

## Contact us

 [info@dreamaderm.com](mailto:info@dreamaderm.com)

 (310) 600-5064



This deck is for informational purposes only and is confidential. Reproduction, distribution, or disclosure of its contents without DREAMADERM's written consent is prohibited. Forward-looking statements are based on current beliefs and may differ from actual results. The Company assumes no obligation to update any projections.